Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1

Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.

Detalles Bibliográficos
Autores principales: Yasuda, Ken‐ichi, Nobeyama, Yoshimasa, Ishiji, Takaoki, Ota, Arihito, Asahina, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669387/
https://www.ncbi.nlm.nih.gov/pubmed/33235741
http://dx.doi.org/10.1002/ccr3.3071
_version_ 1783610558827724800
author Yasuda, Ken‐ichi
Nobeyama, Yoshimasa
Ishiji, Takaoki
Ota, Arihito
Asahina, Akihiko
author_facet Yasuda, Ken‐ichi
Nobeyama, Yoshimasa
Ishiji, Takaoki
Ota, Arihito
Asahina, Akihiko
author_sort Yasuda, Ken‐ichi
collection PubMed
description Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.
format Online
Article
Text
id pubmed-7669387
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76693872020-11-23 Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1 Yasuda, Ken‐ichi Nobeyama, Yoshimasa Ishiji, Takaoki Ota, Arihito Asahina, Akihiko Clin Case Rep Case Reports Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate. John Wiley and Sons Inc. 2020-06-26 /pmc/articles/PMC7669387/ /pubmed/33235741 http://dx.doi.org/10.1002/ccr3.3071 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Yasuda, Ken‐ichi
Nobeyama, Yoshimasa
Ishiji, Takaoki
Ota, Arihito
Asahina, Akihiko
Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
title Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
title_full Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
title_fullStr Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
title_full_unstemmed Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
title_short Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
title_sort effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669387/
https://www.ncbi.nlm.nih.gov/pubmed/33235741
http://dx.doi.org/10.1002/ccr3.3071
work_keys_str_mv AT yasudakenichi effectsofimatinibmesylateoncutaneousneurofibromasassociatedwithneurofibromatosistype1
AT nobeyamayoshimasa effectsofimatinibmesylateoncutaneousneurofibromasassociatedwithneurofibromatosistype1
AT ishijitakaoki effectsofimatinibmesylateoncutaneousneurofibromasassociatedwithneurofibromatosistype1
AT otaarihito effectsofimatinibmesylateoncutaneousneurofibromasassociatedwithneurofibromatosistype1
AT asahinaakihiko effectsofimatinibmesylateoncutaneousneurofibromasassociatedwithneurofibromatosistype1

Ejemplares similares